PVH Corp.
PVH
$92.02
-1.04%
PVH Corp. designs and markets branded apparel across more than 40 countries, with its Calvin Klein and Tommy Hilfiger labels now generating virtually all revenue following the divestiture of most smaller brands; the company operates roughly 1,400 standalone stores, about 1,500 shop-in-shops and concessions, e-commerce sites, and a licensing and wholesale network spanning department stores and specialty accounts. PVH is best characterized as a brand-licensing and wholesale platform in the global apparel industry, monetizing two globally recognized designer trademarks through a capital-light royalty stream (roughly $94 million in royalty revenue) layered atop a large owned retail and wholesale operation. The current investor debate centers on whether PVH is a deep-value turnaround or a structurally challenged wholesaler: shares have rallied sharply year-to-date on improving sentiment and a Q2 earnings beat, yet the June sell-off triggered by weak forward guidance and Middle East geopolitical risk to the EMEA business, plus a deeply negative GAAP quarter (Q2 net loss of $102.9 million), keeps the bull case contested. Analysts remain split, with recent rating actions skewing cautious (JP Morgan cut to Underweight in August, BofA to Underperform in June) even as value-oriented coverage has flagged the stock as a potential bargain on discounted multiples and strong free cash flow.…
PVH
PVH Corp.
$92.02
Related headlines
Investment Opinion: Should I buy PVH Today?
Rating: Hold with a value-tilted constructive bias. The core thesis is that PVH's 0.33x sales and 0.62x book multiples already discount persistent margin compression, while $715 million of TTM free cash flow (roughly a 24% FCF yield on the $2.97 billion market cap) and a 63.03% Q2 gross margin provide a hard asset-value floor that limits permanent capital loss. The analyst tape is split — 5 Buy ratings (Jefferies, Needham, Goldman Sachs, BTIG, UBS) against JP Morgan's Underweight and BofA's Underperform — and with no published consensus target, the view must be anchored on the two-analyst FY EPS average of $13.81, which implies a forward PE of roughly 6.5x at $89.95.
Supporting evidence is heavily valuation- and cash-flow-driven rather than growth-driven. The stock trades at 0.33x PS versus a historical band of roughly 1.19x-3.37x and a branded-apparel sector norm of 1.0-1.5x, a 65-75% discount; PB of 0.62x sits at the very bottom of its 0.62x-1.38x multi-year range. Revenue is contracting at -3.24% year-over-year and trailing net margin is just 0.28%, but gross margin expanded to 63.03% from 57.04% a year earlier, and Q2 operating cash flow of $382.9 million covered capex of $36.5 million by 10.5x. The forward multiple of ~6.5x on $13.81 of estimated EPS means even the low-end $13.56 estimate prices in substantial skepticism, so the risk/reward skews favorably if operating margins merely normalize toward the +5.19% to +5.86% levels seen in Q2 2025 and Q1 2026.
The biggest risks that could invalidate this thesis are (1) a renewed guidance cut tied to EMEA geopolitical weakness that keeps revenue declining beyond -3.24%, (2) failure to rein in the $1.11 billion SG&A load and $400.2 million of other expenses that drove Q2 operating margin to -9.10%, and (3) another earnings-driven gap down like the 26.5% June collapse from $98.00 to $72.01. This Hold would upgrade to Buy if Q3/Q4 shows operating margin returning above +5% with revenue stabilizing, or if the stock pulls back toward the $72-$75 support shelf without fundamental deterioration; it would downgrade to Sell if gross margin slips below 60% or free cash flow turns negative on a trailing basis. Valuation verdict: undervalued relative to its own history and peers on sales and book, but fairly-to-fully valued on EV/EBITDA of 12.68x — the discount is real but conditional on earnings normalization.
Sign up to view all
PVH 12-Month Price Forecast
PVH presents a classic deep-value setup where the market has priced in persistent earnings impairment — 0.33x sales and 0.62x book sit at the bottom of multi-year ranges — while the underlying brand economics (63.03% gross margin) and cash generation ($715 million TTM FCF) remain intact. The forward multiple of roughly 6.5x on the $13.81 two-analyst EPS average means the bull case requires only earnings normalization, not growth, but the -3.24% revenue decline and the -9.10% Q2 operating margin show that normalization is not yet underway. Momentum is a tailwind (+32.63% YTD, +24.80% relative strength YTD) but the stock is extended at roughly 92% of its 180-day range and just reversed -2.52% from $92.28, leaving it vulnerable to profit-taking near the $97.30 resistance. I would upgrade to bullish on evidence that operating margin returns above +5% with revenue stabilizing, or on a pullback toward the $72-$75 support shelf that improves the risk/reward; I would downgrade to bearish if gross margin slips below 60% or trailing free cash flow turns negative, which would confirm the value-trap thesis.
Wall Street consensus
Coverage is thin, with only 2 analysts contributing EPS and revenue estimates (average FY EPS of $13.81, range $13.56-$14.27, and average revenue of $9.474 billion, range $9.34-$9.72 billion), and no consensus average price target is provided in the dataset, so implied upside cannot be calculated from a target price. The institutional ratings tape is more informative: of the 10 recent actions, the distribution skews mixed-to-cautious — Buy ratings from Jefferies, Needham, Goldman Sachs, BTIG, and UBS (5), Equal Weight from Wells Fargo (1), Neutral from BofA (1), and Underweight/Underperform from JP Morgan (2 actions) and BofA (1) — with the notable pattern being downgrades rather than upgrades (JP Morgan cut to Underweight in August, BofA cut to Underperform in June). The consensus therefore leans cautiously neutral-to-bullish on fundamentals but with deteriorating sell-side conviction, and the absence of a published consensus target limits the signal value of the analyst community.
The estimate range is relatively tight (EPS $13.56-$14.27, a spread of about 5%; revenue $9.34-$9.72 billion, a spread of about 4%), which signals reasonable conviction in the near-term earnings trajectory even though the rating distribution is split. The high end of estimates would imply a forward PE of roughly 6.3-6.6x at the current $89.95 price — extremely cheap for a branded-apparel company — suggesting the bull case rests on earnings normalization and multiple re-rating rather than aggressive growth assumptions, while the low end still implies a sub-7x forward multiple, meaning even the bear case prices in substantial skepticism. The key limitation is coverage depth: with only 2 analysts providing estimates and no consensus target, PVH exhibits the characteristics of a mid-cap with limited institutional sponsorship, which raises the risk of inefficient price discovery and elevated volatility around earnings — consistent with the -30.66% max drawdown and the 26.5% single-quarter collapse observed this year.
Bulls vs Bears: PVH Investment Factors
The bear case currently has slightly stronger near-term evidence: revenue is contracting at -3.24%, Q2 produced a $102.9 million net loss with -9.10% operating margins, and the sell-side tape shows downgrades (JP Morgan to Underweight, BofA to Underperform) rather than upgrades. The bull case, however, rests on harder valuation and cash-flow data — 0.33x sales, 0.62x book, a ~24% FCF yield on $715 million TTM free cash flow, and a 63% gross margin — that suggests the market is over-penalizing temporary earnings impairment. The single most important tension is whether the 63% gross margin can be converted back into positive operating income through SG&A discipline and revenue stabilization; if it can, the sub-7x forward multiple re-rates sharply, but if EMEA weakness and the $1.11 billion SG&A load persist, the low multiple proves a value trap. Momentum and relative strength (+24.80% YTD) currently favor the bulls, but the absence of a consensus target and thin two-analyst coverage mean conviction should remain moderate until the next earnings print clarifies the margin trajectory.
Bullish
- Deep-value multiples at multi-year lows: At $89.95, PVH trades at just 0.33x sales and 0.62x book versus historical PS ranges of roughly 1.19x-3.37x and PB of 0.62x-1.38x, placing it at or below the very bottom of its multi-year band. The 0.33x PS is a 65-75% discount to the typical 1.0-1.5x branded-apparel sector range, implying the market has already priced in persistent margin compression.
- Robust free cash flow and high FCF yield: TTM free cash flow of $715 million against a market cap of roughly $2.97 billion implies an FCF yield of about 24%, and Q2 2026 operating cash flow of $382.9 million covered capex of just $36.5 million (10.5x coverage). This cash engine funds operations and buybacks even while GAAP earnings are impaired, anchoring the value case.
- Gross margin structurally healthy at 63%: Q2 2026 gross margin rose to 63.03% from 57.04% a year earlier and 58.57% in Q1 2026, showing the core brand economics remain intact. The gap between a 63% gross margin and a -9.10% operating margin is driven by a $1.11 billion SG&A load and $400.2 million in other expenses, suggesting recoverable operating leverage rather than structural decay.
- Strong momentum and relative strength: PVH is up 32.63% YTD and 14.83% over the past month, with relative strength of +24.80% YTD and +19.82% over one month versus a -4.99% SPY one-month return. The stock has round-tripped its June collapse and is pushing toward the $97.30 November high, signaling genuine idiosyncratic leadership rather than beta drift.
Bearish
- Revenue contracting and guidance weak: Q2 2026 revenue of $2.097 billion fell 3.24% year-over-year from $2.167 billion, and management's weak forward outlook tied to EMEA geopolitical risk suggests stagnation rather than inflection. With product revenue of $2.257 billion dwarfing the $94.4 million royalty stream, PVH's fortunes hinge on owned wholesale and retail sell-through that is currently shrinking.
- GAAP profitability has evaporated: Q2 2026 produced a net loss of $102.9 million (EPS -$2.23) and negative EBITDA of -$123 million, a dramatic swing from Q2 2025 net income of $224.2 million. Trailing net margin of 0.28% and ROE of 0.53% confirm bottom-line profitability is essentially gone, and negative interest coverage of -8.56x in Q2 shows weak quarters strain the P&L.
- Deteriorating sell-side conviction: Of 10 recent rating actions, the pattern is downgrades rather than upgrades: JP Morgan cut to Underweight in August and BofA cut to Underperform in June, alongside a Neutral from BofA and Equal Weight from Wells Fargo. With only 2 analysts providing estimates and no consensus price target, the stock exhibits limited institutional sponsorship and elevated price-discovery risk.
- Severe earnings-driven gap risk: The stock collapsed roughly 26.5% from $98.00 on June 3 to $72.01 by June 25 after weak guidance, and the period max drawdown was -30.66%. This demonstrates high event-driven volatility around earnings that requires careful position sizing regardless of the valuation appeal.
PVH Technical Analysis
PVH is in a choppy but net-positive recovery trend: the stock is up 18.37% over the past year and 32.63% year-to-date, and at $89.95 it sits roughly 92% of the way through its 180-day range of approximately $68.51 (September low) to $97.30 (November high). That positioning near the top of the range signals momentum leadership rather than a falling-knife setup, but it also means the stock is extended relative to its own recent base and vulnerable to profit-taking, as evidenced by the -2.52% single-day pullback on the latest close. Notably, PVH has massively outperformed the S&P 500, with relative strength of +24.80% YTD and +19.82% over the past month versus a -4.99% SPY one-month return, confirming genuine idiosyncratic strength rather than beta-driven drift.
Short-term momentum is clearly accelerating: the stock gained 14.83% over the past month and 2.71% over three months, meaning the bulk of the recent move is very fresh and the one-month trend is far stronger than the three-month trend. This acceleration follows a violent mid-year drawdown — the stock collapsed from $98.00 on June 3 to $72.01 by June 25 (a roughly 26.5% peak-to-trough decline) and then based in the low $70s through September before a powerful October-November rally from $74.90 on October 5 to $97.30 on November 4. The 6-month change of just 0.53% versus the 1-month gain of 14.83% captures this V-shaped pattern: the stock has round-tripped its losses and is now pushing into new relative-high territory, a classic momentum re-acceleration signal, though the sharp -2.52% reversal on the most recent session (from $92.28 to $89.95) hints at near-term exhaustion after a 30% run off the September low.
Key technical levels are well defined: resistance sits at the $97.30 November high, and a decisive breakout above that level would confirm the recovery as a new uptrend and likely invite momentum and value funds to add exposure; support rests at the $68.51 September low, with intermediate support around the $72-$75 shelf that held repeatedly through the summer and early fall. A breakdown below $72 would invalidate the recovery structure and re-open the September lows. Volatility is meaningful — the maximum drawdown over the period was -30.66%, and the stock's 26.5% single-quarter collapse demonstrates gap risk around earnings (the June 4 plunge followed guidance) — so position sizing should account for high event-driven volatility even though beta is not provided in the dataset.
Beta
—
—
Max Drawdown
-30.7%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
+20.3%
Cumulative gain past year
| Period | PVH Return | S&P 500 |
|---|---|---|
| 1m | +12.7% | -2.4% |
| 3m | +12.7% | -2.3% |
| 6m | +15.8% | +2.8% |
| 1y | +20.3% | +11.3% |
| ytd | +35.7% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PVH Fundamental Analysis
Revenue is contracting at the top line: Q2 2026 revenue of $2.097 billion fell 3.24% year-over-year versus $2.167 billion in Q2 2025, and the multi-quarter trend is uneven — Q1 2026 revenue of $2.025 billion was up modestly from $1.984 billion a year earlier, while Q4 2025 revenue of $2.505 billion compared against $2.372 billion in Q4 2024. The product segment dominates at $2.257 billion versus just $94.4 million in royalty revenue, meaning PVH's fortunes hinge on owned wholesale and retail sell-through rather than the higher-margin licensing stream; the modest revenue decline, combined with management's weak forward outlook tied to EMEA geopolitical risk, suggests the growth trajectory is stagnating rather than inflecting, which caps multiple expansion potential and makes the investment case dependent on margin recovery and cash return rather than top-line growth.
Profitability is highly volatile and currently impaired on a GAAP basis: Q2 2026 produced a net loss of $102.9 million (EPS -$2.23) and negative EBITDA of -$123 million, a dramatic swing from Q1 2026 net income of $88 million and Q2 2025 net income of $224.2 million. The gross margin remains structurally healthy at 63.03% in Q2 2026 (up from 57.04% a year earlier and 58.57% in Q1 2026), but operating margin collapsed to -9.10% in Q2 2026 from +5.86% in Q1 2026 and +5.19% in Q2 2025, driven by a $1.11 billion SG&A load and $400.2 million in other expenses; the trailing net margin of just 0.28% and ROE of 0.53% confirm that bottom-line profitability has essentially evaporated. The gap between a 63% gross margin and a negative operating margin is the crux of the bear case — it signals that PVH's cost structure and one-off charges are consuming nearly all gross profit, and the investment thesis requires either SG&A discipline or a revenue rebound to restore operating leverage.
Balance sheet and cash generation are the strongest part of the story: free cash flow TTM is $715 million, Q2 2026 operating cash flow was $382.9 million against capex of only $36.5 million (a 10.5x capex coverage ratio), and the debt-to-equity ratio of 0.897 is moderate for an apparel company with heavy lease and inventory obligations. The current ratio of 1.517 indicates adequate liquidity, cash stood at $965.9 million at quarter-end, and the $715 million FCF against a market cap of roughly $2.97-$4.29 billion implies a very high FCF yield (roughly 17-24%), underscoring that the company can fund operations and modest buybacks internally despite GAAP losses. The caveat is working-capital volatility — Q1 2026 free cash flow was -$86 million and Q3 2025 was -$85.1 million — so cash generation is seasonal and lumpy, and the negative interest coverage in Q2 (-8.56x) shows that weak quarters can strain the P&L even if annual cash flow remains robust.
Quarterly Revenue
$2.1B
2026-08
Revenue YoY Growth
-3.2%
YoY Comparison
Gross Margin
63.0%
Latest Quarter
Free Cash Flow
$715000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PVH Overvalued?
Because trailing net income is barely positive (EPS of $0.0085, net margin 0.28%) and the most recent quarter was a loss, the trailing PE of 118.5x is economically meaningless; I therefore lead with the price-to-sales ratio of 0.33x and the price-to-book ratio of 0.62x as the primary valuation anchors, supplemented by EV/EBITDA of 12.68x and a price-to-free-cash-flow ratio of roughly 4.37x. The forward PE of -1.25x is a data artifact of negative or near-zero forward earnings estimates and should be disregarded; the more telling signal is that the stock trades at just 0.33x sales and 0.62x book — deep-value territory that implies the market is pricing in substantial doubt about earnings normalization despite $715 million in trailing free cash flow.
Against apparel-industry norms, PVH's multiples are at a steep discount: a PS of 0.33x versus a typical branded-apparel sector range of roughly 1.0-1.5x represents a 65-75% discount, and a PB of 0.62x versus a sector average near 1.5-2.0x is a 60-70% discount, while EV/EBITDA of 12.68x is roughly in line to modestly above the sector's high-single-digit to low-double-digit range. The discount is partly justified by the -3.24% revenue decline, the 0.28% net margin, and the 0.53% ROE — all far below sector norms — but the 63% gross margin and $715 million FCF suggest the market is over-penalizing temporary earnings impairment, which is the core of the value argument advanced by bullish coverage.
Historically, PVH has traded at much richer multiples: its PS ratio ranged from roughly 1.19x to 3.37x over the past several years (including 2.00x in Q1 2026 and 1.95x in Q2 2026 on the historical-ratio series), and its PB ranged from about 0.62x to 1.38x, so the current 0.33x PS and 0.62x PB sit at or below the very bottom of the multi-year band. That positioning suggests the market is pricing in pessimistic expectations — persistent margin compression and revenue erosion — and any evidence of stabilization (gross margin already at 63%, FCF at $715 million) could drive meaningful multiple re-rating; conversely, if the EMEA weakness and SG&A burden persist, the low multiple could prove a value trap rather than a bargain.
PE
118.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~15x
vs. Industry Avg
21.3x
Industry PE ~21.3x*
EV/EBITDA
12.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the collapse of GAAP profitability despite healthy gross margins. Q2 2026 delivered a net loss of $102.9 million (EPS -$2.23) and negative EBITDA of -$123 million, with operating margin falling to -9.10% from +5.19% a year earlier as a $1.11 billion SG&A load and $400.2 million in other expenses consumed nearly all of the 63.03% gross profit. Revenue is contracting at -3.24% year-over-year, and with product revenue of $2.257 billion versus only $94.4 million in royalty revenue, PVH is heavily concentrated in owned wholesale and retail sell-through rather than the higher-margin licensing stream. Cash generation is robust at $715 million TTM FCF but seasonal and lumpy — Q1 2026 free cash flow was -$86 million and Q3 2025 was -$85.1 million — and negative Q2 interest coverage of -8.56x shows weak quarters can strain the balance sheet despite a moderate 0.897 debt-to-equity ratio and 1.517 current ratio. Market and competitive risks stem from the stock's positioning after a sharp rally and the deteriorating sell-side tape. PVH has gained 32.63% YTD and 14.83% in the past month, sitting roughly 92% of the way through its 180-day range, which leaves it extended and vulnerable to profit-taking near the $97.30 resistance; the -2.52% reversal on the latest session hints at near-term exhaustion. The rating distribution skews cautious — JP Morgan cut to Underweight in August and BofA to Underperform in June — and with only 2 analysts providing estimates and no consensus target, price discovery is inefficient and volatility around earnings is elevated. EMEA geopolitical risk flagged in the June guidance cut remains a live threat to the international business, and the broader rotation out of cyclicals into defensives (SPY -4.99% over one month) could pressure a consumer-cyclical apparel name even with its strong relative strength. The worst-case scenario is a renewed guidance cut tied to EMEA weakness combined with continued SG&A bloat that keeps operating margins negative, triggering another earnings-driven gap down like the 26.5% single-quarter collapse from $98.00 to $72.01 in June. In that chain of events, the stock would retest the $68.51 September low, representing roughly -24% from the current $89.95, and a broader risk-off tape could push toward the -30.66% max drawdown level implied by the period low. Investors should size positions for this event-driven downside, as the absence of a consensus target and thin coverage removes the usual valuation floor that analyst support would provide.
FAQ
The most severe risk is financial: Q2 2026 produced a $102.9 million net loss and -9.10% operating margin as $1.11 billion of SG&A and $400.2 million of other expenses consumed nearly all of a 63.03% gross margin, and revenue is contracting at -3.24% year-over-year. Second is event-driven volatility — the stock fell 26.5% from $98.00 to $72.01 in June on weak guidance, and the period max drawdown was -30.66%, so a second guidance cut could retest the $68.51 low, roughly -24% from $89.95. Third is deteriorating sell-side conviction and thin coverage: JP Morgan cut to Underweight in August and BofA to Underperform in June, with only two analysts providing estimates and no consensus target, which removes a valuation floor and raises price-discovery risk. Fourth is macro and sector rotation — PVH is a consumer-cyclical apparel name with a 0.897 debt-to-equity ratio, and a risk-off tape (SPY -4.99% over one month) could compress the multiple even with its strong +24.80% YTD relative strength.
The base case (50% probability) targets $90-$105, assuming revenue stabilizes in the -3% to 0% range, gross margin holds at 60-63%, SG&A discipline restores modestly positive operating margins, and FY EPS tracks the $13.56-$14.27 consensus band while the multiple stays near 6.5-7.5x forward. The bull case (25%) targets $110-$125 if operating margin returns above +5% to +6% and the multiple re-rates toward 8-9x, breaking the $97.30 November high. The bear case (25%) targets $68-$78 if a second EMEA-driven guidance cut combines with persistent SG&A bloat and negative operating margins, retesting the $68.51 September low. The base case is most likely because the 63.03% gross margin and $715 million TTM free cash flow are intact while the -3.24% revenue decline and -9.10% operating margin show normalization is not yet underway; the key assumption is that the $1.11 billion SG&A load is right-sized without further one-off charges.
PVH screens undervalued on sales and book value but only fairly valued on cash-flow multiples. The trailing PE of 118.5x is meaningless given a 0.28% net margin and a Q2 loss, so the relevant anchors are 0.33x PS versus a historical 1.19x-3.37x band and a branded-apparel sector norm of 1.0-1.5x (a 65-75% discount), and 0.62x PB at the very bottom of its 0.62x-1.38x range. EV/EBITDA of 12.68x, however, is roughly in line to modestly above the sector's high-single-digit to low-double-digit range, and the price-to-free-cash-flow ratio of about 4.37x is the most compelling metric. The market is therefore pricing in persistent margin compression and revenue erosion rather than a normal cyclical trough. If gross margin holds near 63% and SG&A is right-sized, the discount should narrow; if EMEA weakness persists, the low multiple is a value trap rather than a bargain.
From a risk/reward standpoint PVH is a reasonable value accumulation candidate but not a high-conviction buy: the stock trades at 0.33x sales and 0.62x book, at or below the bottom of its multi-year bands, and generates $715 million of TTM free cash flow against a roughly $2.97 billion market cap, an FCF yield near 24% that provides a hard asset-value floor. The two-analyst FY EPS average of $13.81 implies a forward multiple of roughly 6.5x at $89.95, so the bull case needs only earnings normalization, not growth. The biggest downside risk is another earnings-driven gap down like the 26.5% June collapse from $98.00 to $72.01, with a retest of the $68.51 September low implying roughly -24% from current levels. It is a good buy primarily for patient value investors who can tolerate that volatility and who see evidence of operating margin recovering above +5%; momentum-chasing buyers at roughly 92% of the 180-day range face a less favorable entry. A pullback toward the $72-$75 support shelf without fundamental deterioration would materially improve the risk/reward.
PVH is better suited to a long-term value holding than to short-term trading, though its event-driven volatility makes position sizing critical. The company is in a mature, contracting phase — revenue fell 3.24% year-over-year and trailing net margin is 0.28% — so the return case depends on multi-quarter margin normalization and multiple re-rating rather than near-term growth, which argues for a holding period of at least 12-18 months to capture a full earnings cycle. Short-term traders face a stock that is roughly 92% of its 180-day range after a 14.83% one-month gain, with a -2.52% reversal on the latest session and demonstrated gap risk of 26.5% in a single quarter around earnings. The dividend is negligible at a 0.25% yield with a 29.6% payout ratio, so there is no income cushion while waiting. A reasonable approach is a staged entry — partial position now and additions on a pullback toward the $72-$75 shelf — with a minimum 12-month horizon and a reassessment at each quarterly print against the +5% operating margin threshold.